5月8日 - ** 癌症制药商Verastem VSTM.O的股票在下午的交易中上涨3%，达到6.89美元
** VSTM称 (link)，美国食品和药物管理局批准了其治疗一种罕见卵巢癌患者的组合疗法。
** 该疗法的品牌名称为 Avmapki Fakzynja Co-pack，适用于曾接受过治疗且 KRAS 基因发生突变的低级别浆液性卵巢癌成人患者。
** 杰富瑞（Jefferies）分析师凯利-施（Kelly Shi）说，这种疗法比传统化疗和常用疗法诺华公司的NOVN.S曲美替尼（trametinib）效果更好，激发了医生们 "强烈的采用热情"。
** 疗法将在一周内上市 - VSTM
** 截至上次收盘，该股今年累计上涨了 29
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.